Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $0.36, with 5.84 million shares of worth about $2.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -78.97% during that period and on Wednesday the price saw a loss of about -0.56%. Currently the company’s common shares owned by public are about 361.49M shares, out of which, 179.54M shares are available for trading.
Stock saw a price change of -6.14% in past 5 days and over the past one month there was a price change of -53.13%. Year-to-date (YTD), LXRX shares are showing a performance of -51.59% which decreased to -85.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $2.59 during that period. The average intraday trading volume for Lexicon Pharmaceuticals Inc shares is 6.49 million. The stock is currently trading -24.75% below its 20-day simple moving average (SMA20), while that difference is down -46.08% for SMA50 and it goes to -72.71% lower than SMA200.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) currently have 361.49M outstanding shares and institutions hold larger chunk of about 34.85% of that.
The stock has a current market capitalization of $129.24M and its 3Y-monthly beta is at 1.10. It has posted earnings per share of -$0.64 in the same period. It has Quick Ratio of 5.44 while making debt-to-equity ratio of 0.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXRX, volatility over the week remained 9.55% while standing at 13.08% over the month.
Stock’s fiscal year EPS is expected to rise by 41.27% while it is estimated to increase by 10.81% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on March 05, 2025 offering a Market perform rating for the stock and assigned a target price range of between $2 and $1 to it. Coverage by H.C. Wainwright stated Lexicon Pharmaceuticals Inc (LXRX) stock as a Buy in their note to investors on June 17, 2024, suggesting a price target of $10 for the stock. On April 30, 2024, Leerink Partners Initiated their recommendations, while on March 07, 2023, Jefferies Initiated their ratings for the stock with a price target of $3. Stock get an Overweight rating from Piper Sandler on August 12, 2022.
